NCT03356860 2024-11-20
B-IMMUNE
Grand Hôpital de Charleroi
Phase 1/2 Completed
Clinical Trials
5 trialsNCT05981014 2023-08-08
Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 1/2 Recruiting
NCT00066443 2023-08-04
Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer
Canadian Cancer Trials Group
Phase 1/2 Completed
NCT00705315 2010-08-19
Docetaxel/Epirubicin/Bevacizumab as First Line Therapy for Metastatic HER2 Negative Breast Cancer
Hellenic Oncology Research Group
Phase 1/2 Completed
NCT00097383 2006-07-19
Study of Alimta and Epirubicin Administered in Patients With Locally Advanced or Metastatic Breast Cancer
Eli Lilly and Company
Phase 1/2 Completed